CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target
Advanced salivary gland carcinomas (SGC) often lack therapeutic options. Agents targeting CD138 have recently shown promising results in clinical trials for multiple myeloma and a preclinical trial for triple-negative breast cancer. Immunohistochemistry for CD138 was performed for all patients who h...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/16/9037 |
| _version_ | 1797409830604898304 |
|---|---|
| author | Marcel Mayer Lisa Nachtsheim Franziska Hoffmann Ferdinand von Eggeling Orlando Guntinas-Lichius Johanna Prinz Jens Peter Klußmann Alexander Quaas Christoph Arolt Philipp Wolber |
| author_facet | Marcel Mayer Lisa Nachtsheim Franziska Hoffmann Ferdinand von Eggeling Orlando Guntinas-Lichius Johanna Prinz Jens Peter Klußmann Alexander Quaas Christoph Arolt Philipp Wolber |
| author_sort | Marcel Mayer |
| collection | DOAJ |
| description | Advanced salivary gland carcinomas (SGC) often lack therapeutic options. Agents targeting CD138 have recently shown promising results in clinical trials for multiple myeloma and a preclinical trial for triple-negative breast cancer. Immunohistochemistry for CD138 was performed for all patients who had undergone primary surgery for SGC with curative intent. Findings were validated using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) imaging. Overall, 111 primary SGC and 13 lymph node metastases from salivary duct carcinomas (SaDu) were evaluated. CD138 expression was found in 60% of all SGC with differing expression across entities (<i>p</i> < 0.01). A mean of 25.2% of the tumor cells in mucoepidermoid carcinoma (MuEp) were positive, followed by epithelial-myoepithelial carcinoma (20.9%), acinic cell carcinoma (16.0%), and SaDu (15.2%). High-/intermediate-grade MuEp showed CD138 expression in a mean of 34.8% of tumor cells. For SaDu, lymph node metastases showed CD138 expression in a mean of 31.2% of tumor cells which correlated with CD138 expression in their primaries (<i>p</i> = 0.01; Spearman’s ρ = 0.71). MALDI-MS imaging confirmed the presence of the CD138 protein in SGC. No significant association was found between clinicopathological data, including progression-free survival (<i>p</i> = 0.50) and CD138 expression. CD138 is expressed in the cell membrane of different entities of SGC and SaDu lymph node metastases and therefore represents a potential target for CD138 targeting drugs. |
| first_indexed | 2024-03-09T04:21:12Z |
| format | Article |
| id | doaj.art-b1982c3d2ea0408c8b7955e7599764ee |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T04:21:12Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b1982c3d2ea0408c8b7955e7599764ee2023-12-03T13:48:09ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-08-012316903710.3390/ijms23169037CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic TargetMarcel Mayer0Lisa Nachtsheim1Franziska Hoffmann2Ferdinand von Eggeling3Orlando Guntinas-Lichius4Johanna Prinz5Jens Peter Klußmann6Alexander Quaas7Christoph Arolt8Philipp Wolber9Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Friedrich-Schiller-University, 07747 Jena, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Friedrich-Schiller-University, 07747 Jena, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Jena University Hospital, Friedrich-Schiller-University, 07747 Jena, GermanyDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, 50937 Cologne, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, GermanyMedical Faculty, Institute of Pathology, University of Cologne, 50937 Cologne, GermanyMedical Faculty, Institute of Pathology, University of Cologne, 50937 Cologne, GermanyDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty, University of Cologne, 50931 Cologne, GermanyAdvanced salivary gland carcinomas (SGC) often lack therapeutic options. Agents targeting CD138 have recently shown promising results in clinical trials for multiple myeloma and a preclinical trial for triple-negative breast cancer. Immunohistochemistry for CD138 was performed for all patients who had undergone primary surgery for SGC with curative intent. Findings were validated using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) imaging. Overall, 111 primary SGC and 13 lymph node metastases from salivary duct carcinomas (SaDu) were evaluated. CD138 expression was found in 60% of all SGC with differing expression across entities (<i>p</i> < 0.01). A mean of 25.2% of the tumor cells in mucoepidermoid carcinoma (MuEp) were positive, followed by epithelial-myoepithelial carcinoma (20.9%), acinic cell carcinoma (16.0%), and SaDu (15.2%). High-/intermediate-grade MuEp showed CD138 expression in a mean of 34.8% of tumor cells. For SaDu, lymph node metastases showed CD138 expression in a mean of 31.2% of tumor cells which correlated with CD138 expression in their primaries (<i>p</i> = 0.01; Spearman’s ρ = 0.71). MALDI-MS imaging confirmed the presence of the CD138 protein in SGC. No significant association was found between clinicopathological data, including progression-free survival (<i>p</i> = 0.50) and CD138 expression. CD138 is expressed in the cell membrane of different entities of SGC and SaDu lymph node metastases and therefore represents a potential target for CD138 targeting drugs.https://www.mdpi.com/1422-0067/23/16/9037salivary gland neoplasmimmunohistochemistryhead and neck cancertargeted therapyCD138Syndecan-1 |
| spellingShingle | Marcel Mayer Lisa Nachtsheim Franziska Hoffmann Ferdinand von Eggeling Orlando Guntinas-Lichius Johanna Prinz Jens Peter Klußmann Alexander Quaas Christoph Arolt Philipp Wolber CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target International Journal of Molecular Sciences salivary gland neoplasm immunohistochemistry head and neck cancer targeted therapy CD138 Syndecan-1 |
| title | CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target |
| title_full | CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target |
| title_fullStr | CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target |
| title_full_unstemmed | CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target |
| title_short | CD138 Is Expressed in Different Entities of Salivary Gland Cancer and Their Lymph Node Metastases and Therefore Represents a Potential Therapeutic Target |
| title_sort | cd138 is expressed in different entities of salivary gland cancer and their lymph node metastases and therefore represents a potential therapeutic target |
| topic | salivary gland neoplasm immunohistochemistry head and neck cancer targeted therapy CD138 Syndecan-1 |
| url | https://www.mdpi.com/1422-0067/23/16/9037 |
| work_keys_str_mv | AT marcelmayer cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT lisanachtsheim cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT franziskahoffmann cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT ferdinandvoneggeling cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT orlandoguntinaslichius cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT johannaprinz cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT jenspeterklußmann cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT alexanderquaas cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT christopharolt cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget AT philippwolber cd138isexpressedindifferententitiesofsalivaryglandcancerandtheirlymphnodemetastasesandthereforerepresentsapotentialtherapeutictarget |